Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P140013/S018

Minerva Endometrial Ablation System

Axora Medical, Inc. · Decision date Feb 12, 2026

FDA DECISIONP140013/S018

What did the FDA decide?

FDA records P140013/S018 as a supplement to PMA P140013, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Feb 12, 2026.

FDA approval order statement

a supplier change for select injection molded components of the Minerva Endometrial Ablation Handpiece
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Obstetrics/Gynecology
Decision date
Feb 12, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P140013/S018
Regulatory pathway
PMA supplement
Product code
MNB
Decision code
OK30
Decision date
Feb 12, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Device, thermal ablation, endometrial.

Product code
MNB
FDA device class
3

For the original device and its historical approval scope, see PMA P140013. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P140013 · Original PMA

    MINERVA ENDOMETRIAL ABLATION SYSTEM

  2. P140013/S018 received

    Application receipt date recorded by FDA.

  3. P140013/S018 · FDA decision

    30-Day Notice

  4. P140013/S019 · Related supplement

    MINERVA ENDOMETRIAL ABLATION SYSTEM

Timeline entries are records held by MedtechLedger for P140013. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P140013

Product / regulatory recordCompanyPathwayDecision dateSource
Axora Medical, Inc.PMA approvalJul 27, 2015FDA
Axora Medical, Inc.PMA supplementNov 5, 2026FDA

Explore the linked device profile

Other records with product code MNB

Product / regulatory recordCompanyPathwayDecision dateSource
Channel Medsystems, Inc.PMA supplementNov 3, 2026FDA
Channel Medsystems, Inc.PMA supplementSep 15, 2026FDA
MICROCUBE, LLCPMA supplementJul 13, 2026FDA
Channel Medsystems, Inc.PMA supplementJul 8, 2026FDA
Channel Medsystems, Inc.PMA supplementDec 18, 2025FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Axora Medical, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1 Independent Dr. Suite 2300, Jacksonville, FL, 32202

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records